S&P Futures
3,792.50+2.00(+0.05%)Dow Futures
30,816.00-12.00(-0.04%)Nasdaq Futures
13,026.50+41.00(+0.32%)
Supernus Pharmaceuticals, Inc. (SUPN)
29.75 0.00 (0.00%)
After hours: 4:16PM EST
Chart Events
Performance Outlook
| Previous Close | 29.22 |
| Open | 29.60 |
| Bid | 27.51 x 1000 |
| Ask | 29.99 x 800 |
| Day's Range | 28.83 - 29.85 |
| 52 Week Range | 13.12 - 29.85 |
| Volume | 568,819 |
| Avg. Volume | 621,351 |
| Market Cap | 1.567B |
| Beta (5Y Monthly) | 1.38 |
| PE Ratio (TTM) | 12.34 |
| EPS (TTM) | 2.41 |
| Earnings Date | Feb 23, 2021 - Mar 01, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.75 |
Fair Value
Related Research
- Investor's Business Daily
Exact Sciences Scores Relative Strength Rating Upgrade; Hits Key Threshold
Exact Sciences saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 75 to 85. As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength. Exact Sciences is now considered extended and out of buy range after clearing a 139.36 buy point in a second-stage cup with handle.
- GlobeNewswire
Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference
ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021, at 9:10 a.m. ET, and will be available for virtual investor meetings. A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of this webcast will be available for 60 days on the Company's website after the conference.About Supernus Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations (“on-off” episodes) in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.See full Prescribing Information for our products here: Trokendi XR, Oxtellar XR, APOKYN, MYOBLOC, and XADAGO.All trademarks are the property of their respective owners.CONTACTS: Jack A. Khattar, President and CEO Jim Kelly, EVP & Chief Financial Officer Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591orINVESTOR CONTACT: Peter Vozzo Westwicke, an ICR Company Office: (443) 213-0505 Mobile: (443) 377-4767 Email: peter.vozzo@westwicke.com
